Patients with diabetic kidney disease can potentially be treated with a new investigational medication that may slow the progress of their illness without harmful side effects to their hearts, according to the results of a global clinical trial announced Friday.
The prescription of potentially inappropriate medications to older adults is linked to increased hospitalizations, and it costs patients, on average, more than $450 per year, according to a new University at Buffalo study.
Hospitalized COVID-19 patients who were taking a daily low-dose aspirin to protect against cardiovascular disease had a significantly lower risk of complications and death compared to those who were not taking aspirin, according to a new study led by researchers at the University of Maryland School of Medicine (UMSOM).
The drug tocilizumab (Actemra) does not reduce the need for breathing assistance with mechanical ventilation or prevent death in moderately ill hospitalized patients with COVID-19, according to a new study led by researchers at Massachusetts General Hospital (MGH).
University of Minnesota Medical School physician researchers studied hydroxychloroquine as a treatment to prevent COVID-19 for those with high-risk for exposure to the virus - health care workers.
A new phase 2 clinical trial found the drug axitinib was able to extend the lives of patients with incurable head and neck cancer by several months, and also identified a subset of patients with a specific mutation for whom the drug is likely to work best.
Sex, age, and severity of disease may be useful in identifying COVID-19 survivors who are likely to have high levels of antibodies that can protect against the disease.
An inhaled monoclonal antibody treatment against the SARS-CoV-2 virus may lead to self-administered therapy for COVID-19, according to preclinical tests. It was discovered at UAB and the Texas Biomedical Research Institute, and it has been licensed for development to Aridis Pharmaceuticals.
With specialized knowledge about medications and how they work to fight cancer, oncology pharmacists and pharmacy technicians play a vital role in patient care and research.
Texas Biomedical Research Institute (Texas Biomed) Professor Luis Martinez-Sobrido, Ph.D., recently released study findings, alongside colleagues at the University of Alabama at Birmingham and Aridis Pharmaceuticals, Inc. indicating that a human monoclonal antibody (hmAb) 1212C2 showed promise for further clinical development for preventative use or as a therapy for SARS-CoV-2, the virus that causes COVID-19. Earlier this year, the consortium of scientists isolated specific B cells from patients infected with SARS-CoV-2 and developed a panel of hmAbs that not only bind to SARS-CoV-2 infected cells, but also neutralize the ability of the virus to infect cells. The hmAb 1212C2 was subsequently licensed to Aridis Pharmaceuticals.
A randomized clinical trial found that drug-eluting stents (DES) with durable polymers are non-inferior to DES with biodegradable polymers in patients with acute coronary syndrome (ACS). Findings were reported today at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT is the world’s premier educational meeting specializing in interventional cardiovascular medicine.
Receiving mail-order prescriptions on time is critical during the ongoing pandemic, as older adults and people with chronic conditions are avoiding leaving their homes.
There is some hope on the horizon for patients diagnosed with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. More than a dozen members of the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) were authors on a study announcing the results showing promise in the fight against ALS that appeared in AANEM’s journal Muscle & Nerve.
Toxicological Sciences features leading research biotransformation, toxicokinetics, and pharmacokinetics; computational toxicology and databases; mixtures toxicology; and more in the October 2020 issue.
There are common vulnerabilities among three lethal coronaviruses, SARS-CoV-2, SARS-CoV-1 and MERS-CoV, such as frequently hijacked cellular pathways, that could lead to promising targets for broad coronavirus inhibition, according to a study by an international research team that includes scientists from the Institute for Biomedical Sciences at Georgia State University.
A research team led by Professor Hongzhe SUN, Norman & Cecilia Yip Professor in Bioinorganic Chemistry, Department of Chemistry, Faculty of Science, and Professor Kwok Yung YUEN, Henry Fok Professor in Infectious Diseases, Department of Microbiology, Li Ka Shing Faculty of Medicine of the University of Hong Kong (HKU), has discovered a novel antiviral strategy for treatment of COVID-19.
The NCCN Oncology Research Program (ORP) plans to evaluate neratinib, a type of tyrosine kinase inhibitor (TKI) that works as a dual inhibitor of the epidermal growth factor receptor 1 (EGFR) and human epidermal growth factor receptor 2 (HER2), supported by a $2-million grant from Puma Biotechnology, Inc.
UCLA researchers have found that a drug that activates the body’s natural defenses by behaving like a virus may also make certain stealthy melanoma tumors visible to the immune system, allowing them to be better targeted by immunotherapy.
Anyone with a smartphone can download the app ViDok, which lets users pick from a library of molecules that might bind to key proteins on the SARS-CoV-2 virus, which causes COVID-19, and then can tweak the molecules to try to find a better fit.
AstraZeneca is advancing into phase 3 clinical trials with an investigational COVID-19 therapy of two long-acting antibodies discovered by Vanderbilt University Medical Center (VUMC) and optimized by AstraZeneca.
A first of its kind drug called vosoritide may increase bone growth in children with achondroplasia, the most common form of dwarfism, according to findings from a recent clinical trial published in The Lancet.
A team led by Penn Medicine has engineered powerful new antimicrobial molecules from toxic proteins found in wasp venom. The team hopes to develop the molecules into new bacteria-killing drugs, an important advancement considering increasing numbers of antibiotic-resistant bacteria which can cause illness such as sepsis and tuberculosis.
The raging lung inflammation that can contribute to death from the flu can be stopped in its tracks by a drug derived from a naturally occurring human protein, a new animal study suggests.
In a new COVID-19 clinical trial, Stuart Cohen at UC Davis Health evaluates the efficacy, safety and tolerability of monoclonal antibody combination in adults exposed to patients with COVID-19. It is the same antibody drug given to President Trump to treat his COVID-19.
A COVID-19 vaccine candidate that underwent extensive preclinical testing this spring and summer shows potent preclinical immune responses — including several that distinguish it from other COVID-19 vaccine approaches — according to a preprint deposited in the BioRxiv repository.
The Society for Obstetric Anesthesia and Perinatology (SOAP),the American Society of Anesthesiologists (ASA), the Society for Pediatric Anesthesia (SPA) the American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) aim to clearly reassure pregnant women that the article “Association Between Epidural Analgesia During Labor and Risk of Autism Spectrum Disorders in Offspring,” a new retrospective database study published in JAMA Pediatrics on October 12th, 2020 does not provide credible scientific evidence that epidurals for pain relief cause autism.
Scientists at Wake Forest School of Medicine have recorded real time changes in dopamine and serotonin levels in the human brain that are involved with perception and decision-making. These same neurochemicals also are critical to movement disorders and psychiatric conditions, including substance abuse and depression.
Seattle Cancer Care Alliance (SCCA), the only National Comprehensive Cancer Network (NCCN)-designated cancer center in Washington state, has been selected as an authorized treatment center to offer brexucabtagene autoleucel, also known by the brand name TecartusTM. It is the first and only chimeric antigen receptor (CAR) T-cell therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).
A University of Delaware research team has devised tiny cargo-carrying systems many times smaller than a human hair, made from molecules called peptides that help provide structure for cells and tissues. The team has reported advances in the nanoparticle design that allow them to control the shape of the nanoparticles to allow them to better bind to tissue in the body and stay in a particular location.
The drug discovery program is focused on the assessment of hundreds of drug candidates in the CDI labs, to find the most promising potential therapies.
Media invited to live Q&A on Oct 7th, 2pm EDT
A pay-for performance program that offers enhanced reimbursement to oncology practices for prescribing high-quality, evidence-based cancer drugs increased use of these drugs without significantly changing total spending on care, Penn Medicine researchers report in a new study published online in the Journal of Clinical Oncology.
A patient at UH Cleveland Medical Center received an AAV8-mediated gene transfer of human Ornithine Transcarbamylase. The infusion was well tolerated and patient was discharged without issue. The gene therapy is part of an international, multi-site trial sponsored by Ultragenyx Pharmaceutical Inc.
Adding an “active choice” nudge to the electronic health record increased statin prescribing for patients with heart disease, but not for those “at-risk”
Researchers at the U.S. Department of Energy’s (DOE) Brookhaven National Laboratory are making progress on several fronts in the battle against COVID-19, the global pandemic sparked by the emergence of a novel coronavirus late last year. This work is part of a worldwide effort to understand the virus and the factors that affect its spread with the aim of devising treatments and other mitigation strategies.
Two-thirds of older adults rely on at least two prescription drugs, and more than half take two or more non-prescription drugs or supplements. But a new poll shows that most haven’t connected with a pharmacist to check for potential clashes among their prescription drugs, non-prescription drugs, and supplements, or the potential to save money by switching to lower-cost options.
Only about one in every 170 children take them. But “orphan drugs” accounted for 1 in every 15 private insurance dollars spent on children’s health care in the United States in 2018, according to a new study. That’s up 65% from just five years before.
J. Silvio Gutkind, PhD, has been named chair of the Department of Pharmacology at UC San Diego School of Medicine.
Columbia Engineering researchers report that Sofosbuvir-terminated RNA is more resistant to the proofreader of SARS-CoV-2, the virus that causes COVID-19, than Remdesivir-terminated RNA. The results of the new study, published today by the Nature Research journal Scientific Reports, support the use of the FDA-approved hepatitis C drug EPCLUSA—Sofosbuvir/Velpatasvir—in combination with other drugs in COVID-19 clinical trials.
Michigan Medicine participated in a large clinical trial which found that, in many cases, appendicitis can be safely and effectively treated with antibiotics instead of surgery.
A study exploring a new combination of therapeutic agents has recently been published in the International Journal of Molecular Sciences, describing dl922-947, an oncolytic adenovirus, and AZD1775, an inhibitor of the DNA damage checkpoint kinase WEE1, and their possible efficacy to treat MPM.
Researchers have used “omics” data containing genetic profiles of drugs to identify the hormone oxytocin as a possible treatment for COVID-19, the disease caused by the novel coronavirus (SARS-CoV-2).
Every year more than 250,000 people undergo surgery for appendicitis, making it one of the 20 most common surgeries performed in the United States. In the largest randomized U.S. study of appendicitis published today in the New England Journal of Medicine, researchers from Henry Ford Health System and 24 other sites around the U.S. report that seven in 10 patients who received antibiotics avoided surgery and that patients who took antibiotics for symptom relief fared no worse in the short term than those who underwent surgery.
A study to determine the effectiveness of the drug IP-00 in producing immune responses as a booster for the eventual vaccine for COVID-19 is being conducted by researchers in the Biophotonics & ImmunoEngineering Laboratory, led by Professor Wei R. Chen in the Stephenson School of Biomedical Engineering at the University of Oklahoma. The OU researchers are collaborating with Immunophotonics, Inc., St. Louis, Missouri, on the study.
Results of a first-of-its-kind clinical trial shed light on when antibiotics instead of surgery might be the better choice for treating appendicitis in some patients, according to results from the national Comparing Outcomes of Antibiotic Drugs and Appendectomy (CODA) trial published today in the New England Journal of Medicine.
The year 2020 can be summarized simply by one word - COVID-19 - as it was the culprit that froze the entire world. For more than 8 months so far, movement between nations has been paralyzed all because there are no means to prevent or treat the virus and the diagnosis takes long.
SEATTLE — Oct. 5, 2020 — Fred Hutchinson Cancer Research Center announced the opening of the COVID-19 Clinical Research Center, or CCRC. Funded by philanthropic donations and public/private partnerships, the CCRC is one of the first stand-alone facilities in the nation designed to test novel interventions to treat and prevent COVID-19.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right